Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: a randomized controlled study

Lung cancer has the highest incidence and mortality among malignant tumors, and lung adenocarcinoma is the most common type of lung cancer [1,2]. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs, hereinafter referred to as TKIs) offer significantly greater efficacy than chemotherapy in patients with TKI-sensitive EGFR mutations, and for this reason, TKIs are now the first-line therapy for advanced lung adenocarcinoma in patients with sensitive EGFR mutations [3,4]. Although the progression-free survival (PFS) of these patients has been extended with the use of TKIs, after 10 –14 months of treatment with first-generation TKIs, acquired resistance usually develops [5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research